ArticleCell reports2014

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Valentina Pirazzoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.